Person:
HACIOSMANOĞLU, EBRU

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
EBRU
Last Name
HACIOSMANOĞLU
Name
Email Address
Birth Date

Filters

20222
Reset filters

Settings

Has files: true × Rights: info:eu-repo/semantics/openAccess ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Synthesis of oleanolic acid hydrazide-hydrazone hybrid derivatives and investigation of their cytotoxic effects on A549 human lung cancer cells
    (2022-01-01T00:00:00Z) Şenol, Halil; Mercümek, Berre; Şahin, Rabia Büşra; Kapucu, Halil Burak; Hacıosmanoğlu, Ebru; ŞENOL, HALIL; MERCÜMEK, BERRE; HACIOSMANOĞLU, EBRU
  • Thumbnail Image
    PublicationOpen Access
    Anti-Inflammatory Effects of Melatonin in Rats with Induced Type 2 Diabetes Mellitus
    (2022-04-01T00:00:00Z) YAPIŞLAR, Hande; HACIOSMANOĞLU, Ebru; Sarioglu, Turkan; Degirmencioglu, Sevgin; Sogut, Ibrahim; Poteser, Michael; Ekmekcioglu, Cem; HACIOSMANOĞLU, EBRU
    Introduction: Insulin resistance is associated with a pro-inflammatory state increasing the risk for complications in patients with type 2 diabetes mellitus (T2DM). In addition to its chronobiotic effects, the pineal hormone melatonin is known to exert anti-inflammatory and antioxidant effects. Melatonin was also suggested to affect insulin secretion. The aim of this study was therefore to investigate the effect of melatonin on inflammation in diabetic rats and to study the possible involvement of the melatonin receptor, MT2. Materials and Methods: Male Sprague Dawley rats were randomly divided into four experimental groups (n = 10 per group): (1) control, (2) streptozotocin/nicotinamide induced diabetes type 2 (T2DM), (3) T2DM treated with melatonin (500 mu g/kg/day), and (4) T2DM treated with melatonin (500 mu g/kg/day for 6 weeks) and the selective MT2 receptor antagonist luzindole (0.25 g/kg/day for 6 weeks). Blood samples were taken for biochemical parameters and various tissue samples (liver, adipose tissue, brain) were removed for immunohistochemistry (IHC), Western blot (WB), and Q-PCR analyses, respectively. Results: Melatonin significantly reduced increased blood levels of liver transaminases (AST, ALT), blood urea nitrogen (BUN), triglyceride, very low-density lipoprotein (VLDL), and cholesterol in diabetic rats with luzindole treatment partly reversing this effect regarding the lipids. Furthermore, the liver and adipose tissues of T2DM rats treated with melatonin showed lower expression of the inflammatory markers IL-1 beta, IL-6, TNF-alpha, and NF-kappa B as compared to the T2DM group without melatonin. The results also showed that the MT2 receptor is at least partly involved in the protective effects of melatonin. Conclusions: Our results suggest that melatonin exerts relevant anti-inflammatory effects on various tissues in type 2 diabetic rats.